Tigecycline: A critical update

Journal of Chemotherapy

Volumn 20, Issue 4, 2008, Pages 411-419

  Shakil, S ^a   Akram, M ^a   Khan, Asad U ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Glycylcycline antibiotic; Hospital infections; Multidrug resistance; Spread of resistance; Tigecycline

Indexed keywords

ANTIEMETIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIGOXIN; DOXYCYCLINE; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; ADJUVANT THERAPY; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PROTEUS; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 52249109555     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.4.411     Document Type: Review

References (54)

1. Amyes SG. Enterococci and streptococci. Int J Antimicrob Agents. 2007; 29(3): S43-52.
2. Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol 2007; 8(5): 259-70.
3. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt). 2007; 8(2): 159-72.
4. Cerda E, Abella A, de la Cal Miguel A. Enteral vancomycin controls methicillin-resistant Staphylococcus aureus endemicity in an intensive care burn unit: a 9-year prospective study. Ann Surg 2007; 245(3): 397-407.
5. Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother. 2007; 41(6): 965-72.
6. Goff DA, Dowzicky MJ. Prevalence and regional variation in methicillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol 2007; 56(Pt 9): 1189-93.
7. Tuckman M, Petersen PJ, Howe AY. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob Agents Chemother 2007; 51(9): 3205-11.
8. Sotto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris). 2007. Pubmed(in process).
9. Tygacil™ (tigecycline) package label. Wyeth Pharmaceuticals, Inc., PA, USA.
10. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56(3): 470-480.
11. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004; 64(1): 63-88.
12. Rubinstein E, Vaughan D. Tigecycline: A novel glycylcyline. Drugs 2005; 65(10): 1317-1336.
13. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: An investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin Ther 2005; 27(1): 12-22.
14. Fluit AC, Florijn A, Verhoef J, Milatovic D. 2005. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49:1636-1638.
15. Olson MW, Ruzin A, Feyfant E, Rush III TS, O'Connell J, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006; 50(6): 2156-2166.
16. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(6): 2065-2069.
17. Draghi, DC, Tench, SL, Jones, ME, et al. Longitudinal analysis of tigecycline (TIG) activity against geographically diverse Staphylococcus aureus (SA), Acinetobacter spp. (AB), and Enterobacteriaceae (EN) exhibiting multi-drug resistant (MDR) phenotypes (abstract). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. American Society of Microbiology, E-0744.
18. Meagher AK, Passarell JA, Cirincione BB. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007; 51(6): 1939-1945.
19. Raad I, Hanna H, Jiang Y. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007; 51(5): 1656-1660.
20. Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob Agents Chemother 2007; 51(4): 1155-1163.
21. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the united states and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50(10): 3479-3484.
22. Package insert. Tygacil (tigecycline) for injection. Philadelphia, PA: Wyeth Pharmaceuticals, June 2005.
23. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49(1): 220-229.
24. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17(1): 12-22.
25. Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Tray SM. Effect of age and sex in single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005; 49(4): 1656-1659.
26. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26(5): 704-714.
27. Sun HK, Ong CT, Umer A et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49(4): 1629-1632.
28. Rodvold K.A., Gotfried M.H., Cwik M., et al. Serum, tissue, and body fluid concentrations of tigecycline after a single 100-mg dose. J Antimicrob Chemother 2006; 58(6): 1221-1229.
29. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25(6): 523-529.
30. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58(2): 256-265.
31. Van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44(4): 943-949.
32. Stein GE, Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43(4): 518-524.
33. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352(14): 1436-1444.
34. Postier RG, Green SL, Klein SR et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26(5): 704-714.
35. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41(5): S341-S353.
36. Murray J, Wilson S, Klein S et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase 2 clinical trial. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, L-739.
37. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41(5): S354-S367.
38. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt). 2007; 8(2): 159-72.
39. Zimmerman JJ, Harper D, Matschke K, Speth J, Raible DG, Fruncillo RJ. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC.
40. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49(1): 220-229.
41. Lefort A, Lafaurie M, Massias L et al. Activity and diffusion of tigecycline(GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47(1): 216-222.
42. Montvale NJ, Drug topics red book.: Thomson Healthcare, 2006.
43. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 2007; 6: 4.
44. Khan AU, Musharraf A. Plasmid-mediated multiple antibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection. Med Sci Monit 2004; 10(11): CR598-602.
45. Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria- a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci DOI 10.1007/s11373-007-9194-y.
46. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy. 2007; 27(8): 1198-201.
47. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. 2007; 59(4): 772-4.
48. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. 2007; 27(7): 980-7.
49. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumabnnii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007; 59(1): 128-31
50. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect 2007: 13 (10): 949-952.
51. Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek Hospitals. Antimicrob Agents Chemother. 2006; 50(9): 3166-3169.
52. Edelstein PH, Weiss WJ, Edelstein MAC. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2003; 47(2): 533-540.
53. Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis. 2007; 39(5): 432-4.
54. Moore IF, Hughes DW, Wright GD. Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry. 2005; 44(35): 11829-35.